Chuan Ning Biotech announced that the cumulative deviation value of the closing price increase of more than 30% for two consecutive trading days (i.e. April 29, 2024 and April 30, 2024) was an abnormal fluctuation in stock trading. After verification, there were no major changes in the company's daily business conditions and internal and external production and operation environment compared to before abnormal fluctuations; the company, controlling shareholders and actual controllers had no important matters relating to the company that should have been disclosed but not disclosed, or important matters in the planning stage.
川宁生物：公司日常经营情况、内外部生产经营环境未发生重大变化
Twining Biotech: There have been no major changes in the company's daily business conditions or internal and external production and operation environment
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.